Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.

TP MacGregor, R Carter, RS Gillies, JM Findlay, C Kartsonaki, F Castro-Giner, N Sahgal, LM Wang, R Chetty, ND Maynard, JB Cazier, F Buffa, PJ McHugh, RA Sharma

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalScientific Reports
Publication statusPublished - May 2018

Cite this